Amgen vs Regeneron Pharmaceuticals
Amgen is the larger business, with $36.75bn of revenue in fiscal 2025 against $14.34bn for Regeneron Pharmaceuticals (2.6 times as much). Amgen grew faster (10.0% against 1.0%). Regeneron Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 31.4% against 21.0%. Regeneron Pharmaceuticals carries less debt relative to equity (6.4% against 630.7%).
| Latest fiscal year | AmgenAMGN, 2025 | Regeneron PharmaceuticalsREGN, 2025 |
|---|---|---|
| Revenue | $36.75bn | $14.34bn |
| Revenue growth | 10.0% | 1.0% |
| Net income | $7.71bn | $4.50bn |
| Operating margin | 24.7% | 24.9% |
| Net margin | 21.0% | 31.4% |
| Return on equity | 106.1% | 14.9% |
| Free cash flow | $8.10bn | $4.08bn |
| Cash | $9.13bn | $3.12bn |
| Total debt | $54.60bn | $1.99bn |
| Debt to equity | 630.7% | 6.4% |
| Dividend per share | $9.66 | — |
| Dividend yield | 2.1% | 0.4% |
| Share buybacks | $0 | $3.44bn |
| Employees | — | 15,410 |
| Market value | $249.43bn | $102.62bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 89 (Strong) | 86 (Strong) |
| Insider trades, 12 months | 0 buys, 14 sales | 0 buys, 105 sales |